Interim Open-Label Results of EDEMA3sm : A Study of Subcutaneous Ecallantide in Patients with Hereditary Angioedema

Interim Open-Label Results of EDEMA3sm : A Study of Subcutaneous Ecallantide in Patients with Hereditary Angioedema

Initial safety data available for 11 patients in the double-blind and open-label phases included 17 AEs, with 3 mild events (headache, injection site reaction, injection site erythema) assessed as related to ecallantide.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2007, Vol.119 (1), p.S276-S276
Hauptverfasser: Li, H.H, Levy, R.J, McNeil, D.L, Schmalbach, T.K
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Medical treatment
Patients
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Initial safety data available for 11 patients in the double-blind and open-label phases included 17 AEs, with 3 mild events (headache, injection site reaction, injection site erythema) assessed as related to ecallantide.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2006.12.451